

- Azab B, Amundson JR, Cioci A, Stuart H, Yakoub D, Avisar E, Moffat F, Livingstone AS, Franceschi D. The Usefulness of the Pretreatment Neutrophil/Lymphocyte Ratio as a Predictor of the 5-Year Survival in Stage 1-3 Triple Negative Breast Cancer Patients. *Breast Care (Basel)*. 2021. (1):43-49.
- Anwar SL, Cahyono R, Avanti WS, Budiman HY, Harahap WA, Aryandono T. Pre-treatment neutrophil-lymphocyte and platelet-lymphocyte ratios as additional markers for breast cancer progression: A retrospective cohort study. *Ann Med Surg (Lond)*. 2021;63:102144.
- Asegaonkar SB, Asegaonkar BN, Takalkar UV, Advani S, Thorat AP. C-Reactive Protein and Breast Cancer: New Insights from Old Molecule. *Int J Breast Cancer*. 2015;2015:145647.
- Aynalem M, Adem N, Wendesson F, et al. Hematological abnormalities before and after initiation of cancer treatment among breast cancer patients attending at the University of Gondar comprehensive specialized hospital cancer treatment center. *PLoS One*. 2022;17(8):e0271895.
- Bates JP, Derakhshandeh R, Jones L, Webb TJ. Mechanisms of immune evasion in breast cancer. *BMC Cancer*. 11;18(1):556.
- Bombonati, A. & Sgroi, D. C. The molecular pathology of breast cancer progression. *J. Pathol*. 223, 307–317 (2011).
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries *CA Cancer J Clin*. 2018;68(6):394-424
- Buonomo, O. C. et al. New insights into the metastatic behavior after breast cancer surgery, according to well-established clinicopathological variables and molecular subtypes. *Plos one 12*, e0184680 (2017).
- Cardoso, F. et al. 4th ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 4). *Ann. Oncol*. 29, 1634–1657 (2018).
- Chen J, Deng Q, Pan Y, et al. Prognostic value of neutrophil-to-lymphocyte ratio in breast cancer. *FEBS Open Bio*. 2015;5:502-507.
- Coffelt SB, Wellenstein MD, de Visser KE. Neutrophils in cancer: neutral no more. *Nat Rev Cancer*. 2016 (7) :431–46.
- Corti C, et al. Targeting brain metastases in breast cancer. *Cancer Treatment Reviews*. 2022. 103:102324.
- David F. LaRosa, MD, and Jordan S. Orange, MD, PhD. Lymphocytes, Philadelphia.
- DeNardo DG, Coussens LM. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. *Breast Cancer Res*. 2007;9(4):212.
- DeSantis CE, Ma J, Gaudet MM, et al. Breast cancer statistics, 2019. *CA Cancer J Clin*. 2019;69(6):438-451. doi:10.3322/caac.21583
- Duijf PHG, Nanayakkara D, Nones K, Srihari S, Kalimutho M, Khanna KK. Mechanisms of Genomic Instability in Breast Cancer. *Trends Mol Med*. 2019;25(7):595-61.
- Dushyanthen S, Beavis PA, Savas P, Teo ZL, Zhou C, Mansour M, et al. Relevance of tumor-infiltrating lymphocytes in breast cancer. *BMC Med*. 2015;13 (1):202.
- Ethier JL, Desautels D, Templeton A, Shah PS, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. *Breast Cancer Res*. 2017;19
- Faria SS, Fernandes PC Jr, Silva MJ, et al. The neutrophil-to-lymphocyte ratio: a narrative review. *Ecancermedicalscience*. 2016;10:702.
- Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I, Lindman H. Breast cancer in young women: poor survival despite intensive treatment. *PLoS One*. 2009;4(11): 7695.



- Gago-Dominguez M, Matabuena M, Redondo CM, et al. Neutrophil to lymphocyte ratio and breast cancer risk: analysis by subtype and potential interactions [published correction appears in *Sci Rep.* 2020;10(1):20641].
- Gondhowiardjo S, Christina N, Ganapati NPD, et al. Five-Year Cancer Epidemiology at the National Referral Hospital: Hospital-Based Cancer Registry Data in Indonesia. *JCO Glob Oncol.* 2021;7:190-203.
- Gupta AK, Joshi MB, Philippova M, Erne P, Hasler P, Hahn S, et al. Activated endothelial cells induce neutrophil extracellular traps and are susceptible to NETosis-mediated cell death. *Febs Lett.* (2010) 584:3193– 7.
- Handojo D, et al. Panduan Penatalaksanaan Kanker *Peraboi 2020*. PERABOI. 2020.p1.
- Hanahan D. Hallmarks of Cancer: New Dimensions. *Cancer Discov.* 2022 Jan 1;12(1):31–46.
- Harbeck N, Penault-Llorca F, Cortes J, et al. Breast cancer. *Nat Rev Dis Primers.* 2019;5(1):66.
- He L, Lv Y, Song Y, Zhang B. The prognosis comparison of different molecular subtypes of breast tumors after radiotherapy and the intrinsic reasons for their distinct radiosensitivity. *Cancer Manag Res.* 2019 ;11:5765-5775.
- Hutajulu SH, Prabandari YS, Bintoro BS, et al. Delays in the presentation and diagnosis of women with breast cancer in Yogyakarta, Indonesia: A retrospective observational study. *PLoS One.* 2022.
- Irvin W Jr, Muss HB, Mayer DK. Symptom management in metastatic breast cancer. *Oncologist.* 2011;16(9):1203-1214. doi:10.1634/theoncologist.2011-0159
- Irwig, L., Macaskill, P. & Houssami, N. Evidence relevant to the investigation of breast symptoms: the triple test. *Breast* 11, 215–220 (2002).
- Iwase T, Sangai T, Sakakibara M, et al. An increased neutrophil-to-lymphocyte ratio predicts poorer survival following recurrence for patients with breast cancer. *Mol Clin Oncol.* 2017;6(2):266-270.
- Joe BN, Burstein HJ, Vora SR. Clinical features, diagnosis, and staging of newly diagnosed breast cancer. *Wolters Kluwer UpToDate.* 2022.
- Joshi H, Press MF. Molecular Oncology of Breast Cancer.In: The Breast Comprehensive Management of Benign and Malignant Disease. *Elsevier.* 2017. p1170.
- Kalli S, Semine A, Cohen S, Naber SP, Makim SS, Bahl M. American Joint Committee on Cancer's Staging System for Breast Cancer, Eighth Edition: What the Radiologist Needs to Know. *Radiographics.* 2018;38(7):1921-1933.
- Kamata A, Hino K, Kamiyama K, Takasaka Y. Very Late Recurrence in Breast Cancer: Is Breast Cancer a Chronic Disease?. *Cureus.* 2022;14(3):e22804.
- Kim Z, Min SY, Yoon CS, et al. The Basic Facts of Korean Breast Cancer in 2012: Results from a Nationwide Survey and Breast Cancer Registry Database. *J Breast Cancer.* 2015;18(2):103-111.
- Lafourcade A, His M, Baglietto L, Boutron-Ruault MC, Dossus L, Rondeau V. Factors associated with breast cancer recurrences or mortality and dynamic prediction of death using history of cancer recurrences: the French E3N cohort. *BMC Cancer.* 2018;18(1):171.
- Lee TH, Chang JH, Jang BS, et al. Protocol for the postoperative radiotherapy in N1 breast cancer patients (PORT-N1) trial, a prospective multicenter, randomized, controlled, non-inferiority trial of patients receiving breast-conserving surgery or mastectomy. *BMC Cancer.* 2022;22(1):1179.
- Liu Y, He M, Zuo WJ, Hao S, Wang ZH, Shao ZM. Tumor Size Still Impacts Prognosis in Breast Cancer With Extensive Nodal Involvement. *Front Oncol.* 2021;11:585613.
- Liu C, Huang Z, Wang Q, et al. Usefulness of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in hormone-receptor-negative breast cancer. *Onco Targets Ther.* 2016;9:4653-4660.



- Lou C, Jin F, Zhao Q, Qi H. Correlation of serum NLR, PLR and HALP with efficacy of neoadjuvant chemotherapy and prognosis of triple-negative breast cancer. *Am J Transl Res.* 2022;14(5):3240-3246.
- Majeed W, Aslam B, Javed I, et al. Breast cancer: major risk factors and recent developments in treatment. *APJCP.* 2014; 15: 3353-3358.
- Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. *Nature.* 2008;454(7203):436-444.
- Mardiah, Harisa, Radita Nur Anggaeni Ginting, Heru Rahmadhany, & Esther Reny Deswani Sitorus. "Correlation between Age and Body Mass Index (BMI) with Histopathological Features of Breast Cancer Patients in RSUP Haji Adam Malik Medan." *Indonesian Journal of Cancer* 15.2 (2021): 46-53.
- McCarthy AM, Barlow WE, Conant EF, et al. Breast Cancer With a Poor Prognosis Diagnosed After Screening Mammography With Negative Results [published correction appears in *JAMA Oncol.* 2018 Jul 1;4(7):1018]. *JAMA Oncol.* 2018;4(7):998-1001.
- Melvin JC, Wulaningsih W, Hana Z, et al. Family history of breast cancer and its association with disease severity and mortality. *Cancer Med.* 2016;5(5):942-949.
- Mishalian I, Bayuh R, Levy L, Zolotarov L, Michaeli J, Fridlender ZG. Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression. *Cancer Immunol Immunother.* 2013;62(11):1745-1756.
- Momenimovahed Z, Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world. *Breast Cancer (Dove Med Press).* 2019;11:151-164.
- Morrow, M., Waters, J. & Morris, E. MRI for breast cancer screening, diagnosis, and treatment. *Lancet* 378, 1804–1811 (2011).
- National Cancer Institute. Breast cancer. 2022. Available from: <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/breast-cancer>
- Nechuta S, Lu W, Zheng Y, et al. Comorbidities and breast cancer survival: a report from the Shanghai Breast Cancer Survival Study. *Breast Cancer Res Treat.* 2013;139(1):227-235.
- Ochuko Orakpoghenor¹, Daniel Onimisi Avazi², Talatu Patience Markus and Olushola Samuel Olaolu. Lymphocytes: *A Brief Review*-Department of Veterinary Pathology, Ahmadu Bello University, Zaria, Nigeria
- Ohtani H, Mori-Shiraishi K, Nakajima M, Ueki H. Defining lymphocyte-predominant breast cancer by the proportion of lymphocyte-rich stroma and its significance in routine histopathological diagnosis. *Pathol Int.* 2015 ; 65 (12):644–51.
- Orditura M, Galizia G, Diana A, et al. Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: a propensity score-matched analysis. *ESMO Open.* 2016;1(2)
- Pedersen RN, Esen BÖ, Mellekjær L, et al. The Incidence of Breast Cancer Recurrence 10-32 Years After Primary Diagnosis. *J Natl Cancer Inst.* 2022;114(3):391-399.
- Peleg Hasson S, Menes T, Sonnenblick A. Comparison of Patient Susceptibility Genes Across Breast Cancer: Implications for Prognosis and Therapeutic Outcomes. *Pharmgenomics Pers Med.* 2020;13:227-238.
- Pistelli M, De Lisa M, Ballatore Z, et al. Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients. *BMC Cancer.* 2015;15:195.
- Ramos-Esquivel A, Rodriguez-Porras L, Porras J. Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors in non-metastatic breast cancer patients from a Hispanic population. *Breast Dis.* 2017;37(1):1-6.
- Ravi S, Alencar AM, Arakelyan J, Xu W, Stauber R, Wang CCI, et al. An Update to Hallmarks of Cancer. *Cureus.* 2022; 7;14(5):1–16.
- Riskesdas. (2018). Riset Kesehatan Dasar 2018. In Kementrian Kesehatan Republik Indonesia
- 3Shah R, Rosso K, Nathanson SD. Pathogenesis, prevention, diagnosis and treatment of breast cancer. *World J Clin Oncol.* 2014;5(3):283-298.



- Schultz. The neutrophil Clyde Department of Biology, The University of Calgary, Alberta, Canada 2BioGram Inc., Ponte Vedra, USA
- Sharma GN, Dave R, Sanadya J, Sharma P, Sharma KK. Various types and management of breast cancer: an overview. *J Adv Pharm Technol Res.* 2010;1(2):109-126.
- Sinaga ES, Ahmad RA, Shivalli S, Hutajulu SH. Age at diagnosis predicted survival outcome of female patients with breast cancer at a tertiary hospital in Yogyakarta, Indonesia. *Pan Afr Med J.* 2018;31:163.
- Slattery, M. L., T. D. Berry, and R. A. Kerber. 1993. Is survival among women diagnosed with breast cancer influenced by family history of breast cancer? *Epidemiology* 4:543–8.
- Solikhah S, Perwitasari DA, Rejeki DSS. Geographic Characteristics of Various Cancers in Yogyakarta Province, Indonesia: A Spatial Analysis at the Community Level. *Asian Pac J Cancer Prev.* 2022;23(4):1231-1238.
- Smolarz B, Nowak AZ, Romanowicz H. Breast Cancer-Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature). *Cancers (Basel)* 14(10):2569.
- Song, H., Kim, H.J., Park, K.N., Kim, S.H., Oh, S.H. & Youn, C.S., 2020, Neutrophil to lymphocyte ratio is associated with in-hospital mortality in older adults admitted to the emergency department, *American Journal of Emergency Medicine*, 40, 133–137.
- Soto-Perez-de-Celis E, Chavarri-Guerra Y, Leon-Rodriguez E, Gamboa-Dominguez A. Tumor-Associated Neutrophils in Breast Cancer Subtypes. *Asian Pac J Cancer Prev.* 2017;18(10):2689-2693.
- Sun YS, Zhao Z, Yang ZN, et al. Risk Factors and Preventions of Breast Cancer. *Int J Biol Sci.* 2017;13(11):1387-1397. Published 2017 Nov 1.
- Tellez-Gabriel M, Knutsen E, Perander M. Current Status of Circulating Tumor Cells, Circulating Tumor DNA, and Exosomes in Breast Cancer Liquid Biopsies. *Int J Mol Sci.* 2020;21(24):945.
- Tigner A, Ibrahim SA, Murray IV. Histology, White Blood Cell. In: *StatPearls*. Treasure Island (FL): *StatPearls* 2022.
- Vano Y, et al. (2018). Optimal cut-off for NLR: Fact or Fantasy? A prospective cohort study in metastatic cancer patients. *Plos one.* 13(4):e0195042.
- Wei B, Yao M, Xing C, Wang W, Yao J, Hong Y, et al. The neutrophil lymphocyte ratio is associated with breast cancer prognosis: an updated systematic review and meta-analysis. *OTT.* 2016 Sep;Volume 9:5567–75.
- Wiener AA, Hanlon BM, Schumacher JR, Vande Walle KA, Wilke LG, Neuman HB. Reexamining Time From Breast Cancer Diagnosis to Primary Breast Surgery. *JAMA Surg.* 2023;158(5):485-492.
- Yersal Ö, Çetinküner S, Aktimur R, et al. Neutrophil/Lymphocyte and Platelet/Lymphocyte Ratios are Not Different among Breast Cancer Subtypes. *Asian Pac J Cancer Prev.* 2017;18(8):2227-2231
- Youlden DR, Cramb SM, Yip CH, Baade PD. Incidence and mortality of female breast cancer in the Asia-Pacific region. *Cancer Biol Med.* 2014;11(2):101-115.
- Zhang W, Shen Y, Huang H, et al. A Rosetta Stone for Breast Cancer: Prognostic Value and Dynamic Regulation of Neutrophil in Tumor Microenvironment. *Front Immunol.* 2020;11:1779.